{"title": "Healthcare Provider Q&A", "author": null, "url": null, "hostname": null, "description": "This Q&A document includes general information about COVID-19 vaccines and questions and answers specific to the vaccines currently in use in BC. <br />", "sitename": null, "date": "2023-09-09", "cleaned_text": "1. National Advisory Committee on Immunization. Canadian Immunization Guide [Internet]. Evergreen ed. Ottawa (ON): Public Health Agency of Canada; 2012 [updated 2020 Dec 24]. Part 3 - Immunization pregnancy and breastfeeding; [cited 2021 Jan10]. Available from: [https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-4-immunization-pregnancy-breastfeeding.html](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-4-immunization-pregnancy-breastfeeding.html) and Gynaecologists of Canada [Internet]. Ottawa (ON): The Society of Obstetricians and Gynaecologists of Canada. SOGC statement on COVID-19 vaccination in pregnancy. 2021 Jan 11 [cited 2021 Jan 13]. Available from: [https://sogc.org/common/Uploaded%20files/Covid%20Information/SOGC_Statement_COVID-19_Vaccination_in_Pregnancy.pdf](https://sogc.org/common/Uploaded%20files/Covid%20Information/SOGC_Statement_COVID-19_Vaccination_in_Pregnancy.pdf) 3. Castillo E and Poliquin V. Immunization in pregnancy. J Obstet Gynaecol Can Myers TR, Moro PL, Oduyebo T, Panagiotakopoulos L, Marquez PL, Olson R, SR, Burkel A, Martin SW, Gee JM, Meaney-Delman DM; CDC v-safe COVID-19 Pregnancy Registry Team. Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. N Engl J Med. 2021 Apr 21. doi: 10.1056/NEJMoa2104983. Epub ahead of print. PMID: 33882218. 5. Public Health Agency of Canada [Internet]. Ottawa (ON): Public Health Agency of Canada. Recommendations on the use of COVID-19 vaccines. 2021 April 23 [cited 2021 April 28]. Available from: [https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci.html](https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci.html) 6. Canadian Rheumatology Association. Recommendations on COVID-19 vaccination in persons with autoimmune rheumatic disease. January 2021. [https://rheum.ca/wp-content/uploads/2021/11/V3_Nov_23_2021_EN.pdf](https://rheum.ca/wp-content/uploads/2021/11/V3_Nov_23_2021_EN.pdf) 7. Chen H, Huang Z, Chang S, Hu M, Lu Q, Zhang Y, Wang H, Xiao Y, Ge Y, Zou Y, Cui F. Immunogenicity and safety of an [https://doi.org/10.1016/j.vaccine.2022.07.033](https://doi.org/10.1016/j.vaccine.2022.07.033) Bourron Fournier M, Moore TM, Pandey A, Perez L, Sater N, Shrestha A, Wague S. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged 65 years: a phase 2, randomised, open-label study. The Lancet Respiratory Medicine. 2022 Apr 1;10(4):392-402. Available from: [https://doi.org/10.1016/S2213-2600(21)00557-9](https://doi.org/10.1016/S2213-2600%2821%2900557-9) 9. Lazarus R, Baos Cappel-Porter Carson-Stevens Clout M, Culliford L, Emmett SR, Garstang J, Gbadamoshi L, Hallis B, Harris RA. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. The Lancet. Dec 18;398(10318):2277-87. Available from: [https://doi.org/10.1016/S0140-6736(21)02329-1](https://doi.org/10.1016/S0140-6736%2821%2902329-1) 10. Toback S, Galiza E, Cosgrove C, Galloway J, Goodman AL, Swift PA, Rajaram S, Graves-Jones A, Edelman J, Burns F, Minassian AM. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine. 2022 Feb 1;10(2):167-79. Available from: [https://doi.org/10.1016/S2213-2600(21)00409-4](https://doi.org/10.1016/S2213-2600%2821%2900409-4) 11. Janssen P, Gaillat J, Launay O, Botelho-Nevers E. Coadministration of seasonal influenza and COVID-19 vaccines: A systematic review of clinical studies. Human Vaccines & Immunotherapeutics. 2022 Oct 14:2131166. Available from: [https://doi.org/10.1080/21645515.2022.2131166](https://doi.org/10.1080/21645515.2022.2131166) 12. Shenyu Bo Xuan Zeng W, Hangjie Z, Qianhui Z, Zhenzhen L, Chuanfu Y, Juan Y, Gang Z. Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine A randomized, open-label, controlled study in healthy adults aged 18 to 59 years in China. Vaccine. 2022 Aug 26;40(36):5356-65. Available from: [https://doi.org/10.1016/j.vaccine.2022.07.021](https://doi.org/10.1016/j.vaccine.2022.07.021) Guarona G. COVID-19 and Seasonal Influenza Vaccination: Cross-Protection, Co-Administration, Combination Vaccines, and Hesitancy. Pharmaceuticals. 2022 Mar 8;15(3):322. Available from: [https://doi.org/10.3390/ph15030322](https://doi.org/10.3390/ph15030322) 14. Centers for Disease Control and Prevention [Internet]. Atlanta (GA): U.S. Department of Health & Human Services. Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States; [updated Jan 6; cited 2021 Jan 8]. 15. Public Health Agency of Canada [Internet]. Ottawa (ON): Public Health Agency of Canada. Summary of updates in the Canadian Immunization guide of August 29, 2022: Updated guidance on COVID-19 vaccines in Canada. 2022 Aug 29 [cited 2022 Aug 29]. Available from: [https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/summary-updates-canadian-immunization-guide-august-29-2022-covid-19-vaccines.html](https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/summary-updates-canadian-immunization-guide-august-29-2022-covid-19-vaccines.html) 16. Public Health Agency of Canada [Internet]. Ottawa (ON): Public Health Agency of Canada. NACI rapid response: Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada. 2021 Mar 8 [cited 2021 Mar 16]. Available from: [https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html](https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html) 17. Saleh E, Moody MA, Walter EB. Effect of antipyretic analgesics on immune responses to vaccination. Hum Vaccin Immunother Sep 19. Das I, Naik SS. The effect of prophylactic antipyretic administration on post-vaccination adverse reactions and antibody response in children: a systematic review. PLoS One [Internet]. 2014 Sep 2 [cited 2021 Jan 10];9(9):e106629. Available from: [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0106629](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0106629) 20. BC Cancer. COVID-19 and Cancer Screening. Does the COVID-19 vaccine affect my screening mammogram? Accessed "}